Full Press Release Details
Precipio announces shareholder update
call to kick off 2020
HAVEN, CT, (January 13, 2020) - Specialty diagnostics company Precipio, Inc. (NASDAQ:
PRPO), announced that on Monday, January 20th at 5pm it will conduct a shareholder update call with regard to several
strategic initiatives for 2020 as well as the current status of IV-cell and Hemescreen deployment and the diversification of our
business model into the products sector.
conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for
the Precipio Inc. conference call. Participants may also pre-register for the conference call at http://dpregister.com/10138459
and will receive a calendar invite and
a direct dial-in number, bypassing the operator.
Listeners interested in submitting questions
in advance should email their questions to investors@precipiodx.com and management will do
its best to address those questions during the call. A replay of the call will be available approximately 24 hours after the call
and may be accessed via the Investors page on Precipio's website, http://www.precipiodx.com/investors.html.
built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed
within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through
its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the
Yale School of Medicine, Harvard's Dana-Farber Cancer Institute and the University of Pennsylvania, Precipio offers a new
standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
Forward-Looking Statements
in this press release constitute "forward-looking statements," within the meaning of federal securities laws, including
statements related to ICP technology, including financial projections related thereto and potential market opportunity, plans and
prospects and other statements containing the words "anticipate," "intend," "may," "plan,"
"predict," "will," "would," "could," "should," and similar expressions,
constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company's
actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors.
Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements
include the known risks, uncertainties and other factors described in the Company's definitive proxy statement filed on May
29, 2018, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and on the Annual Report on
Form 10-K for the year ended December 31, 2018 as well as the Company's prior filings and from time to time in the Company's
subsequent filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the
actual results, events and performance to differ materially from those referred to in such statements. All information in this
press release is as of the date of the release and the Company does not undertake any duty to update this information, including
any forward-looking statements, unless required by law.